Navigation Links
Foamix Receives US Patent on Novel Foam Technology
Date:8/24/2009

NESS ZIONA, Israel, August 24 /PRNewswire/ -- Foamix Ltd., a leading developer of topical foams for dermatology and gynecology, announced today that it has been awarded US Patent #7575739 pertaining to its foam technology. The patent covers unique foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.

Dr. Dov Tamarkin, the Company's CEO stated, "The novelty of our foam technology platform is that it enables facile delivery of active agents to the inflicted site. Our foams are breakable - they are easily applied to the sensitive area of wounds and burns and they are absorbed readily into the treated area."

Foamix expends significant resources on protecting its intellectual property. To date, Foamix has five issued U.S. patents covering its OilGel(TM) and topical foam technology platforms. An additional 70 U.S. patent applications, protecting its proprietary foam platforms are under prosecution, covering compositions, applications, methods of use and delivery devices. The Company employs leading U.S. patent counsel (Wilmer Hale, Boston) as well as an in-house intellectual property team.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with 10 pharmaceutical and cosmetic companies on 12 projects in the development of proprietary dermatological and gynecologic foam drugs. Additionally, the Company has an extensive in-house pipeline of dermatological and gynecological drugs in foam presentation.

Foamix holds 5 US patents and has 70 patents pending in the United States.

For additional information please visit http://www.foamix.co.il

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il


'/>"/>
SOURCE Foamix Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
2. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
3. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
4. SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM)
5. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
6. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
8. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
9. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
10. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
11. REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):